Merck-AstraZeneca breast cancer drug Lynparza improves long-term survival, clinical trial shows

Merck AstraZeneca breast cancer drug Lynparza improves long term survival clinical trial

Lynparza (olaparib), a product of Fortune 500 pharmaceutical firm Merck and Fortune 500 Europe company…

More posts

Merck-AstraZeneca breast cancer drug Lynparza improves long-term survival, clinical trial shows

December 21, 2024
Syphilis originated in the Americas, ancient DNA shows, but European colonialism spread it widely

December 21, 2024
Maplebear CEO Simo Fidji sells $886,832 in stock By Investing.com

December 21, 2024
Vince stock soars to 52-week high of $4.82 amid robust gains By Investing.com

December 21, 2024